Syndicated Loan Financing

29. March 2021

BGP advised Swixx Biopharma AG on a EUR 52 mio. loan facility agreement with a syndicate of three major banks.

Bader Gnehm & Partner advised Swixx Biopharma AG, one of the largest and fastest growing international commercialization platforms for innovative biopharma and self-medication companies in Central and Eastern Europe, regarding a EUR 52 million revolving credit facility agreement with the major banks UBS Switzerland AG, Credit Suisse (Switzerland) AG and Citibank Europe plc. The facility included an option to request an increase of the loan up to EUR 80 million.

Swixx Biopharma AG operates fully owned subsidiaries across Central and Eastern Europe and Russia, with 600 employees and sales estimate exceeding 260 million Euros in 2021. The company has gathered outstanding rare disease, oncology-hematology, specialty and self- medication talent under one roof.

Bader Gnehm & Partner assisted Swixx Biopharma AG in the negotiations and advised on all Swiss legal aspects of the complex transaction. The team was led by Oliver Gnehm (Partner) and further consisted of Thomas Gysin (Associate).